Literature DB >> 28150386

An Emerging Female Phenotype with Loss-of-Function Mutations in the Aristaless-Related Homeodomain Transcription Factor ARX.

Tessa Mattiske1,2, Ching Moey1,2, Lisenka E Vissers3, Natalie Thorne4,5,6, Peter Georgeson6,7, Madhura Bakshi8, Cheryl Shoubridge1,2.   

Abstract

The devastating clinical presentation of X-linked lissencephaly with abnormal genitalia (XLAG) is invariably caused by loss-of-function mutations in the Aristaless-related homeobox (ARX) gene. Mutations in this X-chromosome gene contribute to intellectual disability (ID) with co-morbidities including seizures and movement disorders such as dystonia in affected males. The detection of affected females with mutations in ARX is increasing. We present a family with multiple affected individuals, including two females. Two male siblings presenting with XLAG were deceased prior to full-term gestation or within the first few weeks of life. Of the two female siblings, one presented with behavioral disturbances, mild ID, a seizure disorder, and complete agenesis of the corpus callosum (ACC), similar to the mother's phenotype. A novel insertion mutation in Exon 2 of ARX was identified, c.982delCinsTTT predicted to cause a frameshift at p.(Q328Ffs* 37). Our finding is consistent with loss-of-function mutations in ARX causing XLAG in hemizygous males and extends the findings of ID and seizures in heterozygous females. We review the reported phenotypes of females with mutations in ARX and highlight the importance of screening ARX in male and female patients with ID, seizures, and in particular with complete ACC.
© 2017 WILEY PERIODICALS, INC.

Entities:  

Keywords:  ARX; Aristaless-related homeobox; LISX2; X-linked lissencephaly; X-linked lissencephaly-2; XLAG; intellectual disability; seizure

Mesh:

Substances:

Year:  2017        PMID: 28150386     DOI: 10.1002/humu.23190

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  4 in total

1.  Deleterious de novo variants of X-linked ZC4H2 in females cause a variable phenotype with neurogenic arthrogryposis multiplex congenita.

Authors:  Suzanna G M Frints; Friederike Hennig; Roberto Colombo; Sebastien Jacquemont; Paulien Terhal; Holly H Zimmerman; David Hunt; Bryce A Mendelsohn; Ulrike Kordaß; Richard Webster; Margje Sinnema; Omar Abdul-Rahman; Vanessa Suckow; Alberto Fernández-Jaén; Kees van Roozendaal; Servi J C Stevens; Merryn V E Macville; Salwan Al-Nasiry; Koen van Gassen; Norbert Utzig; Suzanne M Koudijs; Lesley McGregor; Saskia M Maas; Diana Baralle; Abhijit Dixit; Peter Wieacker; Marcus Lee; Arthur S Lee; Elizabeth C Engle; Gunnar Houge; Gyri A Gradek; Andrew G L Douglas; Cheryl Longman; Shelagh Joss; Danita Velasco; Raoul C Hennekam; Hiromi Hirata; Vera M Kalscheuer
Journal:  Hum Mutat       Date:  2019-08-21       Impact factor: 4.878

2.  Heterozygous loss of function of IQSEC2/Iqsec2 leads to increased activated Arf6 and severe neurocognitive seizure phenotype in females.

Authors:  Matilda R Jackson; Karagh E Loring; Claire C Homan; Monica Hn Thai; Laura Määttänen; Maria Arvio; Irma Jarvela; Marie Shaw; Alison Gardner; Jozef Gecz; Cheryl Shoubridge
Journal:  Life Sci Alliance       Date:  2019-08-22

3.  Neuropathology of genetically defined malformations of cortical development-A systematic literature review.

Authors:  Stefanie Brock; Filip Cools; Anna C Jansen
Journal:  Neuropathol Appl Neurobiol       Date:  2021-02-14       Impact factor: 8.090

4.  Heterozygous nonsense ARX mutation in a family highlights the complexity of clinical and molecular diagnosis in case of chromosomal and single gene disorder co-inheritance.

Authors:  Alice Traversa; Enrica Marchionni; Agnese Giovannetti; Maria L Genovesi; Noemi Panzironi; Katia Margiotti; Giulia Napoli; Francesca Piceci Sparascio; Alessandro De Luca; Francesco Petrizzelli; Massimo Carella; Francesco Cardona; Silvia Bernardo; Lucia Manganaro; Tommaso Mazza; Antonio Pizzuti; Viviana Caputo
Journal:  Mol Genet Genomic Med       Date:  2020-06-10       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.